Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at two upcoming investor conferences: 22nd Annual Needham Virtual Healthcare ConferenceApril 17, 20233:00 p.m. ET – fireside chat Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 20, 20233:00 p.m. ET – panel discussion A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for patients with cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com. Nkarta Media/Investor Contact:Greg MannNkarta, [email protected]